Cancers Clinical Trials

5 recruiting

Cancers Trials at a Glance

212 actively recruiting trials for cancers are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Not Applicable with 60 trials, with the heaviest enrollment activity in Houston, Guangzhou, and Beijing. Lead sponsors running cancers studies include National Cancer Institute (NCI), Tianjin Medical University Cancer Institute and Hospital, and M.D. Anderson Cancer Center.

Treatments under study

About Cancers Clinical Trials

Looking for clinical trials for Cancers? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cancers trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cancers clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 212 trials

Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

Disorders of Sex Development (DSD)Pediatric and Adolescent Cancers of the Genital TractReproductive Endocrine Conditions in Puberty+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)11,000 enrolled1 locationNCT04717349
Recruiting

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Thoracic CancersLung Cancer NOSMalignant Pleural Mesotheliomas NOS+2 more
National Cancer Institute (NCI)1,559 enrolled1 locationNCT00242723
Recruiting
Phase 1Phase 2

First-in-human Study of 7MW4911 in GI Cancer

GI Cancers
Mabwell (Shanghai) Bioscience Co., Ltd.200 enrolled5 locationsNCT07216560
Recruiting
Not Applicable

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

Breast Cancers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University112 enrolled9 locationsNCT07095023
Recruiting
Phase 2

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Not Applicable

Communication About Sexual Health in Gynecologic Cancer

Gynecologic Cancers
Fox Chase Cancer Center200 enrolled1 locationNCT06904339
Recruiting

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer

Gastrointestinal CancerCancer of Gastrointestinal TractNon-GI Cancers
National Cancer Institute (NCI)550 enrolled1 locationNCT01313442
Recruiting

The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

Neuroendocrine CarcinomaSmall Cell Lung Cancers
Samsung Medical Center797 enrolled6 locationsNCT02688894
Recruiting

Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study

Gynecologic CancersSexual Wellness
Casa di Cura Dott. Pederzoli200 enrolled6 locationsNCT07557342
Recruiting
Phase 1Phase 2

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Advanced Liver Cancers
Hoffmann-La Roche518 enrolled33 locationsNCT04524871
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 1Phase 2

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting

A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
AstraZeneca2,100 enrolled14 locationsNCT07404202
Recruiting
Phase 1Phase 2

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Advanced Solid Cancers
BioNTech SE245 enrolled8 locationsNCT07186842
Recruiting
Phase 1

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers

PIK3CA-Mutated Cancers
Hoffmann-La Roche30 enrolled8 locationsNCT06496568
Recruiting
Not Applicable

Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

HPVTonsil CancerOropharyngeal Cancers+1 more
Georgetown University30 enrolled2 locationsNCT06902623
Recruiting
Phase 1Phase 2

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

Ovarian CancerPancreatic CarcinomaAdvanced Solid Tumors+1 more
Evopoint Biosciences Inc.350 enrolled24 locationsNCT06799637